Analysts Expect BioDelivery Sciences International, Inc

Cornelia Mascio
Ottobre 13, 2017

(NASDAQ:BDSI) to report sales of $8.89 million for the current quarter, Zacks Investment Research reports. Next quarter's EPS is estimated at $-0.22 with next year's EPS projected to be $-0.64. Citigroup Inc holds 0% of its portfolio in BioDelivery Sciences International, Inc. The share price has moved forward from its 20 days moving average, trading at a distance of 4.62% and stays 4.05% away from its 50 days moving average.

Analysts expect Cross Timbers Royalty Trust (NYSE:CRT) to report $0.28 EPS on November, 7.They anticipate $0.01 EPS change or 3.70% from last quarter's $0.27 EPS.

03/14/2016 - BioDelivery Sciences International, Inc. had its "buy" rating reiterated by analysts at Laidlaw.

05/31/2014 - BioDelivery Sciences International, Inc. was downgraded to "sell" by analysts at TheStreet. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by ($0.04). The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.45 million. During the same period in the previous year, the company earned ($0.31) EPS. The firm's revenue was up 74.0% compared to the same quarter a year ago.

A number of equities analysts have recently issued reports on BDSI shares. Janney Montgomery Scott lifted their price target on BioDelivery Sciences International from $3.00 to $4.00 and gave the company a "fair value" rating in a report on Monday, July 24th. (NASDAQ:BDSI). Driehaus Cap Mgmt owns 0.01% invested in BioDelivery Sciences International, Inc. Roth Capital maintained it with "Buy" rating and $9 target in Friday, March 11 report. (NASDAQ:BDSI). New York-based Hrt Ltd Liability Company has invested 0.08% in BioDelivery Sciences International, Inc. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The stock has "Buy" rating by Cantor Fitzgerald on Wednesday, August 23. Zacks Investment Research cut shares of BioDelivery Sciences International from a "buy" rating to a "hold" rating in a research note on Monday, July 17th. The firm has "Market Perform" rating by FBR Capital given on Friday, August 5. "(BDSI) Expected to Announce Earnings of -$0.23 Per Share" was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this news story on another website, it was stolen and reposted in violation of US & global trademark and copyright legislation. Valley Advisers Inc has invested 0.04% in BioDelivery Sciences International, Inc. By watching how many shares are trading hands and looking for any changes in that activity, trading opportunities can be spotted along with a deeper understanding of the reliability of other indicators on the stock. The stock has a 50-day moving average of $2.95 and a 200-day moving average of $2.58. BDSI fell -3.28%, plunged -1.67% and advanced 68.57% in the week, one month and six months, respectively. The company has market cap of $160.88 million.

In related news, CEO Mark A. Sirgo sold 65,405 shares of the stock in a transaction dated Wednesday, September 20th. The total value of its holdings increased 1,266.7%. Following the completion of the sale, the insider now directly owns 1,509,262 shares of the company's stock, valued at approximately $4,286,304.08. The analyst recommendations from a month ago are 0 Buy, 7 Strong Buy, 0 Sell, 0 Hold and 0. The shares were sold at an average price of $2.75, for a total transaction of $179,863.75. Insiders have sold a total of 402,127 shares of company stock valued at $1,142,798 in the last quarter.

Several institutional investors have recently modified their holdings of BDSI. Finally, NEXT Financial Group Inc boosted its position in shares of BioDelivery Sciences International by 9.3% in the second quarter. 492667 shares were traded on BioDelivery Sciences International, Inc.'s last session. Stonepine Capital Management, LLC added to its investment by buying 632,853 shares an increase of 22.2% from 03/31/2017 to 06/30/2017. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company's stock worth $210,000 after buying an additional 91,297 shares during the period. For the next financial year, analysts forecast that the company will post sales of $49.46 million per share, with estimates ranging from $44.33 million to $55.40 million. Grandeur Peak Global Advisors Llc owns 1.14 million shares or 0.46% of their USA portfolio. Finally, GSA Capital Partners LLP lifted its stake in shares of BioDelivery Sciences International by 10.1% in the 2nd quarter.

Hikari Power Ltd increased Biodelivery Sciences International Inc (BDSI) stake by 127.23% reported in 2017Q2 SEC filing. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE